GO:0035860 glial cell-derived neurotrophic factor receptor signaling pathway: Neurotrophic Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0035860 describes the series of molecular signals initiated by a ligand binding to a glial cell-derived neurotrophic factor (GDNF) receptor.
• The pathway is activated by GDNF family ligands (GDNF, neurturin, artemin, persephin) binding to GDNF family receptor alpha (GFRα) co-receptors and the RET receptor tyrosine kinase.
• GDNF receptor signaling is critical for the survival, development, and maintenance of dopaminergic, motor, and sensory neurons, and for kidney morphogenesis.
• Dysregulation of GDNF signaling is implicated in Parkinson's disease, addiction, stroke, and cancer metastasis.
• GDNF and its receptors are expressed in the ovary and regulate follicular development, oocyte maturation, and steroidogenesis.
• Research tools include knockout and knock-in mouse models, conditional alleles, and CRISPR-based editing to dissect pathway components.
Description
The glial cell-derived neurotrophic factor (GDNF) receptor signaling pathway (GO:0035860) is a biological process that begins when a ligand binds to a GDNF receptor on the cell surface, triggering a cascade of intracellular signals. GDNF was originally identified as a trophic factor for midbrain dopaminergic neurons, and its receptor system is now known to be essential for the development and maintenance of multiple neuronal populations and non-neuronal tissues. The pathway is activated by the GDNF family ligands (GFLs), which include GDNF, neurturin, artemin, and persephin. These ligands bind to glycosylphosphatidylinositol (GPI)-anchored co-receptors of the GDNF family receptor alpha (GFRα) family, which then recruit and activate the RET receptor tyrosine kinase. This ligand-receptor complex initiates downstream signaling through pathways such as MAPK/ERK, PI3K/AKT, and PLCγ, leading to diverse cellular responses including survival, proliferation, differentiation, and migration. Researchers study GO:0035860 because of its profound implications for human health and disease. GDNF signaling is a major survival factor for dopaminergic neurons, and its dysfunction has been linked to Parkinson's disease and other neurodegenerative conditions. In the periphery, GDNF signaling is required for kidney development and spermatogenesis, and it regulates ovarian function. Moreover, GDNF signaling has been implicated in addiction, ischemic stroke, and cancer metastasis, where it can promote tumor cell survival and dissemination. Understanding the precise molecular mechanisms of this pathway is therefore critical for developing targeted therapies. The pathway is also a model system for studying receptor tyrosine kinase signaling, GPI-anchored co-receptors, and neurotrophic factor biology. Recent studies have explored the expression of GDNF receptors during development and the protective effects of GDNF signaling in retinal ganglion cells under hypoxia/reoxygenation. This article provides a comprehensive overview of GO:0035860, covering its definition, core mechanisms, key genes, regulation, disease relevance, and research methods, with a focus on CRISPR-based approaches for functional dissection.
glial cell-derived neurotrophic factor receptor signaling pathway At A Glance
| GO ID | GO:0035860 |
|---|---|
| GO term | glial cell-derived neurotrophic factor receptor signaling pathway |
| Ontology | biological_process |
| Synonym | GDNF receptor signaling pathway; glial cell derived neurotrophic factor receptor signaling pathway; glial cell-derived neurotrophic factor receptor signalling pathway; glial cell line-derived neurotrophic factor receptor signalling pathway |
| Major function | Transduces signals from GDNF family ligands to regulate neuronal survival, differentiation, and non-neuronal tissue development |
| Ligands | GDNF, neurturin, artemin, persephin |
| Core receptors | GFRα1-4 co-receptors and RET receptor tyrosine kinase |
| Key downstream pathways | MAPK/ERK, PI3K/AKT, PLCγ |
| Associated diseases | Parkinson's disease, addiction, ischemic stroke, cancer metastasis |
What Is GO:0035860?
GO:0035860, the glial cell-derived neurotrophic factor receptor signaling pathway, is defined as the series of molecular signals initiated by a ligand binding to a glial cell-derived neurotrophic factor receptor. In simpler terms, it is the entire process that occurs inside a cell after a GDNF-family ligand docks onto its receptor, converting that extracellular binding event into a coordinated set of intracellular signals that alter cell behavior.
Why Is glial cell-derived neurotrophic factor receptor signaling pathway Important in Cell Biology?
GO:0035860 is critically important because it governs fundamental processes in nervous system development and function, and its dysregulation contributes to a wide range of human diseases. GDNF signaling is the most potent survival factor known for midbrain dopaminergic neurons, which degenerate in Parkinson's disease. The pathway also plays essential roles in kidney organogenesis, spermatogenesis, and ovarian physiology. In cancer, GDNF signaling can be hijacked to promote metastasis, as shown in breast cancer bone-to-meninges metastasis. Furthermore, GDNF signaling is involved in addiction and ischemic stroke, making it a target for therapeutic intervention. Understanding this pathway at the molecular level is therefore essential for both basic neurobiology and translational medicine.
• Essential for the survival and maintenance of midbrain dopaminergic neurons, which are lost in Parkinson's disease.
• Required for kidney development and spermatogenesis; knockout of GDNF or RET leads to renal agenesis and lack of enteric neurons.
• Regulates ovarian follicular development, oocyte maturation, and steroidogenesis.
• Implicated in addiction and reward circuitry, with GDNF modulating drug-seeking behavior.
• Protects neurons from ischemic injury, as shown in focal ischemic stroke models.
• Promotes cancer metastasis, including breast cancer spread to the meninges.
• Mediates neuroprotection in retinal ganglion cells under hypoxia/reoxygenation.
• Serves as a model for GPI-anchored co-receptor signaling and receptor tyrosine kinase activation.
• Potential therapeutic target for neurodegenerative diseases, addiction, and cancer.
• Expression of GDNF receptors is developmentally regulated in brainstem nuclei such as the nucleus ambiguus.
What Happens During glial cell-derived neurotrophic factor receptor signaling pathway?
Ligand Binding and Receptor Complex Assembly
In simple terms: First, a growth factor molecule grabs onto a receptor on the cell surface, like a key fitting into a lock.
The pathway is initiated when a GDNF family ligand (GDNF, neurturin, artemin, or persephin) binds with high affinity to a GPI-anchored GFRα co-receptor (GFRα1-4) on the cell surface. This binding induces the recruitment of the RET receptor tyrosine kinase, forming a multi-component signaling complex. The ligand-GFRα-RET complex is the minimal functional unit required for signal transduction. Each ligand shows preferential binding to specific GFRα co-receptors: GDNF binds GFRα1, neurturin binds GFRα2, artemin binds GFRα3, and persephin binds GFRα4.
RET Activation and Autophosphorylation
In simple terms: The receptor inside the cell gets switched on by adding phosphate groups to itself.
Upon complex assembly, RET molecules undergo dimerization and trans-autophosphorylation on specific intracellular tyrosine residues. This autophosphorylation creates docking sites for adaptor and signaling proteins. The activated RET kinase then phosphorylates downstream targets, initiating multiple signaling cascades. This step is a critical checkpoint for pathway activation and is tightly regulated.
Downstream Signaling Cascades
In simple terms: The activated receptor sends signals along several different routes inside the cell.
Activated RET recruits and activates several downstream pathways, including the MAPK/ERK pathway (via Shc/Grb2/SOS/Ras/Raf/MEK/ERK), the PI3K/AKT pathway (via Gab1/Gab2 and PI3K), and the PLCγ pathway. These cascades lead to changes in gene expression, cytoskeletal dynamics, and cell survival. The specific downstream response depends on cell type and context, allowing GDNF to exert pleiotropic effects.
Biological Outcomes
In simple terms: The final result is that the cell survives, grows, or changes its behavior.
The ultimate outcomes of GDNF receptor signaling include promotion of neuronal survival, differentiation, neurite outgrowth, and synaptic plasticity. In non-neuronal tissues, it regulates cell proliferation, migration, and branching morphogenesis, as seen in kidney development. In the ovary, GDNF signaling influences follicular development and oocyte maturation. In pathological contexts, it can promote cancer cell survival and metastasis.
Termination and Regulation
In simple terms: The signal is eventually turned off to prevent overactivity.
Signal termination involves receptor internalization, degradation, and negative feedback loops. For example, the protein Sprouty and SHP2 can attenuate RET signaling. Additionally, the expression levels of ligands, co-receptors, and RET are tightly regulated. Dysregulation of these termination mechanisms can lead to prolonged signaling, which is associated with diseases such as cancer and neurodegeneration.
Key Genes Involved in GO:0035860 glial cell-derived neurotrophic factor receptor signaling pathway
The following genes encode the core components and regulators of the GDNF receptor signaling pathway, as established in the literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| GDNF | Primary ligand; binds GFRα1 to activate RET | Knockout leads to renal agenesis and loss of enteric neurons; studied in Parkinson's disease and addiction |
| NRTN | Ligand; binds GFRα2 | Supports parasympathetic and sensory neurons; potential therapeutic for neuropathy |
| ARTN | Ligand; binds GFRα3 | Regulates sympathetic neuron development and pain signaling |
| PSPN | Ligand; binds GFRα4 | Expressed in thyroid and other tissues; less studied |
| GFRA1 | GPI-anchored co-receptor for GDNF | Essential for GDNF signaling; knockout causes similar phenotype to GDNF knockout |
| GFRA2 | Co-receptor for neurturin | Mediates neurturin signaling in neurons |
| GFRA3 | Co-receptor for artemin | Involved in sympathetic neuron development |
| GFRA4 | Co-receptor for persephin | Expressed in thyroid; function less characterized |
| RET | Receptor tyrosine kinase; signal-transducing subunit | Mutations cause Hirschsprung disease and medullary thyroid carcinoma; central to pathway |
| SHC1 | Adaptor protein; binds phosphotyrosine on RET | Links RET to MAPK/ERK pathway |
| GRB2 | Adaptor protein; binds SHC and SOS | Mediates Ras activation |
| GAB1 | Docking protein; activates PI3K | Links RET to PI3K/AKT pathway |
| PLCγ | Phospholipase; generates IP3 and DAG | Mediates calcium and PKC signaling |
| SOS1 | Guanine nucleotide exchange factor for Ras | Activates MAPK cascade |
| RAS | Small GTPase; activates Raf | Oncogenic in many cancers; downstream of RET |
| MAPK1/3 | ERK kinases; regulate gene expression | Mediate survival and proliferation signals |
| AKT1 | Serine/threonine kinase; promotes survival | Key downstream effector of PI3K |
| SPRY2 | Negative regulator of RTK signaling | Attenuates RET signaling |
How Is glial cell-derived neurotrophic factor receptor signaling pathway Regulated?
The GDNF receptor signaling pathway is regulated at multiple levels. Ligand availability is controlled by expression, secretion, and extracellular matrix binding. Receptor levels are modulated by transcription and trafficking. Negative feedback mechanisms include Sprouty proteins, which inhibit the Ras/MAPK pathway, and SHP2, which dephosphorylates RET. Additionally, the pathway cross-talks with other signaling systems, such as BDNF and GLP1R signaling in brainstem neurons. In the ovary, hormonal regulation influences GDNF and GFRα expression. Dysregulation of these control mechanisms can lead to pathological states, including cancer and neurodegeneration.
glial cell-derived neurotrophic factor receptor signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| GDNF | Parkinson's disease; addiction; kidney agenesis | GDNF knockout mouse; conditional knockout in dopaminergic neurons; overexpression in striatum |
| RET | Hirschsprung disease; medullary thyroid carcinoma | RET knockout mouse; point-mutation knock-in (e.g., RET51 isoform) |
| GFRA1 | Kidney agenesis; enteric nervous system defects | GFRA1 knockout mouse; conditional knockout |
| GFRA2 | Neurodegeneration; sensory neuron loss | GFRA2 knockout mouse |
| ARTN | Pain; sympathetic neuron development | ARTN knockout mouse; overexpression |
Parkinson's Disease and Neurodegeneration
GDNF is a potent survival factor for midbrain dopaminergic neurons, which degenerate in Parkinson's disease. Reduced GDNF signaling has been observed in Parkinson's disease models, and GDNF administration protects these neurons in animal studies. The pathway is also implicated in other neurodegenerative conditions, such as ischemic stroke, where GDNF signaling promotes neuronal survival. In retinal ganglion cells, GDNF signaling protects against hypoxia/reoxygenation injury.
Addiction and Psychiatric Disorders
GDNF signaling in the ventral tegmental area and nucleus accumbens modulates responses to drugs of abuse. Animal studies show that GDNF infusion reduces drug-seeking behavior, while inhibition enhances it. This suggests that GDNF receptor signaling is a key regulator of addiction-related plasticity.
Cancer Metastasis
GDNF signaling can be exploited by cancer cells to promote survival and metastasis. In breast cancer, neural signaling pathways including GDNF are hijacked for bone-to-meninges metastasis. RET activation by GDNF family ligands can also drive tumorigenesis in medullary thyroid carcinoma and other cancers. Targeting this pathway is a potential therapeutic strategy.
Developmental and Kidney Disorders
Mutations in GDNF or RET cause Hirschsprung disease and congenital anomalies of the kidney and urinary tract. GDNF signaling is essential for ureteric bud branching and nephron formation; knockout mice lack kidneys. In the ovary, dysregulated GDNF signaling may contribute to reproductive disorders.
From glial cell-derived neurotrophic factor receptor signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does GDNF signaling protect dopaminergic neurons in vivo? | GDNF overexpression or knockout in mouse midbrain; toxin-induced Parkinson's models |
| What is the role of RET kinase activity in kidney development? | RET point-mutation knock-in (kinase-dead) mouse |
| How does GDNF signaling affect addiction behavior? | Conditional GDNF knockout in VTA; viral overexpression |
| Does GDNF signaling promote cancer metastasis? | Orthotopic breast cancer models with GDNF knockdown or overexpression |
| What are the downstream effectors of GDNF in neurons? | Tagged knock-in of RET or GFRα1 for proteomics; RNA-seq after GDNF stimulation |
| Is GDNF signaling required for ovarian function? | Ovary-specific GDNF or GFRA1 knockout mice |
How to Study the glial cell-derived neurotrophic factor receptor signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Western blot | Phosphorylation of RET, ERK, AKT | Assess pathway activation after ligand stimulation |
| Co-immunoprecipitation | Protein-protein interactions (e.g., RET-GFRα) | Detect receptor complex assembly |
| RNA-seq | Transcriptional changes | Identify downstream target genes |
| CRISPR knockout | Loss-of-function phenotypes | Determine gene requirement in pathway |
| Immunofluorescence | Protein localization and expression | Study receptor distribution in tissues |
| Neurite outgrowth assay | Functional neuronal differentiation | Measure GDNF-induced neurite extension |
| Survival assay | Cell viability | Test neuroprotective effects of GDNF |
| In vivo models | Behavioral and histological outcomes | Evaluate therapeutic potential in Parkinson's models |
Genetic Knockout and Knock-in Models
CRISPR/Cas9-mediated knockout of GDNF, GFRA1, or RET in cell lines and mice is a primary method to study pathway function. Conditional knockout using Cre/loxP allows tissue-specific ablation. Knock-in of point mutations (e.g., kinase-dead RET) can dissect specific domains. These models have revealed essential roles in kidney and nervous system development.
Biochemical Assays for Pathway Activation
Western blotting for phosphorylated RET, ERK, and AKT is used to measure pathway activation after ligand stimulation. Co-immunoprecipitation can detect receptor complex assembly. These methods are standard for validating GDNF signaling in vitro.
Transcriptomics and Proteomics
RNA-seq after GDNF stimulation or knockout identifies downstream transcriptional changes. Proteomics can uncover novel interacting partners of RET and GFRα. These approaches provide unbiased insights into pathway effectors.
Imaging and Functional Assays
Immunofluorescence can localize GDNF receptors in tissues, such as the nucleus ambiguus during development. Neurite outgrowth assays and survival assays measure functional outcomes. In vivo imaging in animal models assesses neuroprotection.
How CRISPR Can Be Used to Study GO:0035860 glial cell-derived neurotrophic factor receptor signaling pathway
Knockout
CRISPR/Cas9 knockout of GDNF, GFRA1, or RET is used to create loss-of-function models. These models are essential for studying the requirement of the pathway in development and disease. For example, GDNF knockout mice exhibit renal agenesis and loss of enteric neurons. In cell lines, knockout of RET abolishes GDNF-induced signaling.
Point Mutation
CRISPR-mediated point mutations can introduce specific amino acid changes to dissect domain functions. For instance, mutating key tyrosine residues in RET can prevent docking of specific adaptors, revealing their contribution to downstream signaling. Point mutations can also model human disease variants, such as RET mutations in Hirschsprung disease.
Knock-in
Knock-in of reporter tags (e.g., GFP, HA) or conditional alleles (e.g., loxP-flanked) allows visualization and spatial control of pathway components. Tagged RET or GFRα1 can be used for proteomics and imaging. Conditional knock-in of GDNF in specific brain regions can test its therapeutic potential.
Overexpression
CRISPR activation (CRISPRa) or transgenic overexpression of GDNF or RET can enhance pathway activity. Overexpression models are used to study neuroprotection and cancer promotion. For example, GDNF overexpression in the striatum protects dopaminergic neurons in Parkinson's models. In cancer, overexpression of GDNF or RET can drive metastasis.
How EDITGENE Supports glial cell-derived neurotrophic factor receptor signaling pathway Research
Researchers studying glial cell-derived neurotrophic factor receptor signaling pathway-related genes often need to determine whether a candidate gene is causally involved in pathway function, disease progression, or therapeutic response. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this discovery, from generating knockout cell lines to performing high-throughput library screens.
Contact EDITGENE today to design your custom CRISPR model for glial cell-derived neurotrophic factor receptor signaling pathway research.
Frequently Asked Questions About glial cell-derived neurotrophic factor receptor signaling pathway
What is GO:0035860?
GO:0035860 is the Gene Ontology term for the glial cell-derived neurotrophic factor receptor signaling pathway, defined as the series of molecular signals initiated by a ligand binding to a GDNF receptor.
What genes are involved in glial cell-derived neurotrophic factor receptor signaling pathway?
Key genes include GDNF, NRTN, ARTN, PSPN, GFRA1-4, and RET, as well as downstream effectors like SHC1, GRB2, and MAPK1.
What is the function of GDNF receptor signaling?
It promotes neuronal survival, differentiation, and non-neuronal tissue development, and regulates ovarian function and kidney morphogenesis.
How is GDNF receptor signaling activated?
It is activated when a GDNF family ligand binds to a GFRα co-receptor, which then recruits and activates the RET receptor tyrosine kinase.
What diseases are associated with GDNF signaling?
Parkinson's disease, addiction, ischemic stroke, Hirschsprung disease, and cancer metastasis.
What are the downstream pathways of GDNF signaling?
The MAPK/ERK, PI3K/AKT, and PLCγ pathways are major downstream cascades.
How can I study GDNF receptor signaling using CRISPR?
CRISPR knockout, point mutation, knock-in, and overexpression models can be used to dissect gene function and pathway mechanisms.
What is the role of RET in GDNF signaling?
RET is the signal-transducing receptor tyrosine kinase that is activated upon ligand-GFRα binding and initiates downstream signaling.
Is GDNF signaling involved in cancer?
Yes, GDNF signaling can promote cancer cell survival and metastasis, as shown in breast cancer bone-to-meninges metastasis.
What model organisms are used to study GDNF signaling?
Mouse models, including knockout and conditional knockout mice, are widely used, along with cell lines and zebrafish.
Conclusion
GO:0035860, the glial cell-derived neurotrophic factor receptor signaling pathway, is a fundamental biological process with critical roles in nervous system development, kidney organogenesis, and ovarian function. Its dysregulation is implicated in major human diseases, including Parkinson's disease, addiction, stroke, and cancer. Understanding the molecular mechanisms of this pathway offers opportunities for therapeutic intervention. CRISPR-based models and screening approaches are powerful tools to dissect gene function and identify new drug targets. EDITGENE provides comprehensive services to support this research, from custom knockout and knock-in cell lines to high-throughput screens.
References
- 1. Whiteley AE et al.. 2024. Breast cancer exploits neural signaling pathways for bone-to-meninges metastasis.. Science 384(6702):eadh5548 PMID: 38900896
- 2. Zhang Z et al.. 2021. Glial Cell Line-Derived Neurotrophic Factor and Focal Ischemic Stroke.. Neurochem Res 46(10):2638-2650 PMID: 33591443
- 3. Blount Q et al.. 2023. Expression of Glial Cell-Derived Neurotrophic Factor Receptors Within Nucleus Ambiguus During Rat Development.. Laryngoscope 133(9):2240-2247 PMID: 36271908
- 4. Feetham CH et al.. 2024. Brainstem BDNF neurons are downstream of GFRAL/GLP1R signalling.. Nat Commun 15(1):10749 PMID: 39737892
- 5. Ron D et al.. 2005. GDNF and addiction.. Rev Neurosci 16(4):277-85 PMID: 16519005
- 6. Saarma M et al.. 1999. Other neurotrophic factors: glial cell line-derived neurotrophic factor (GDNF).. Microsc Res Tech 45(4-5):292-302 PMID: 10383122
- 7. Chang HM et al.. 2019. Neurotrophins and glial cell line-derived neurotrophic factor in the ovary: physiological and pathophysiological implications.. Hum Reprod Update 25(2):224-242 PMID: 30608586
- 8. Kobayashi-Otsugu M et al.. 2024. FK962 protects retinal ganglion cell under hypoxia/reoxygenation: Possible involvement of glial cell line-derived neurotrophic factor signaling pathway.. Exp Eye Res 248:110099 PMID: 39284507
